Results 131 to 140 of about 28,855 (210)

In silico receptor binding and ex vivo nasal epithelial membrane permeation studies of selected phytocannabinoids. [PDF]

J Cannabis Res
Van Niekerk SE, Cloete T, Van der Kooy F, Hamman JH.   +3 more
europepmc   +1 more source

Phase I Metabolism of Novel Phencyclidine Derivative 3‐Cl‐PCP: In Vitro Studies With Pooled Human Liver Microsomes and Investigation of a Post‐Mortem Case

Drug Testing and Analysis, Volume 18, Issue 8, Page 1036-1053, August 2026.
A fatal 3‐chloro‐phencyclidine (3‐Cl‐PCP) intoxication was investigated by analyzing postmortem samples and a pooled human liver microsomes assay. Tentative metabolite identification was performed by liquid chromatography‐quadrupole time‐of‐flight mass spectrometry (LC‐QTOF‐MS). Seven phase I metabolites were identified.
Johannes Kutzler, Tobias Veit, Thomas Keller, Volker Auwärter   +3 more
wiley   +1 more source

Radical Revelations: The Interplay of Nitrosative Stress, the Endocannabinoid System, and Treatment of Age-Related Disorders. [PDF]

Int J Mol Sci
Davis A, Casmedes IY, Burton MD.
europepmc   +1 more source

In Vitro Metabolism of Δ8‐, Δ9‐, and Δ10‐THC in Human Hepatocytes: Distinct Δ10‐THC Biotransformation and Implications for Drug Testing

Drug Testing and Analysis, Volume 18, Issue 8, Page 1114-1121, August 2026.
Δ8‐THC and Δ9‐THC showed comparable metabolic profiles. In contrast, Δ10‐THC underwent extensive glucuronidation and hydroxylation, with only minor formation of a carboxy metabolite, indicating a markedly different metabolic pathway. These differences may increase the risk of misidentification and misinterpretation in cannabis drug testing.
Robert Kronstrand, Henrik Green, Markus Loh, Fabian Rüttimann, Manuela Carla Monti   +4 more
wiley   +1 more source

Reversible detrusor acontractility associated with heavy cannabis use: A case report. [PDF]

Urol Case Rep
Rotar M, Hawlina S.
europepmc   +1 more source

Cannabidiol reduces atypical absence seizures and epileptic spasms in a Gabrb3+/D120N mouse model of Lennox–Gastaut syndrome

Epilepsia Open, Volume 11, Issue 4, Page 1263-1275, August 2026.
Abstract Objective Lennox–Gastaut syndrome (LGS) is a drug‐resistant developmental and epileptic encephalopathy (DEE). Preclinical drug development for LGS is constrained by a lack of syndrome‐relevant animal models. We aimed to evaluate a Gabrb3+/D120N knock‐in (KI) mouse model of LGS by quantifying atypical absence seizures and epileptic spasms and ...
Thomas Harman, Laura A. Sharman, Ka Lai Yip, Miguel Bedoya‐Pérez, Vaishali Janve, Jonathon C. Arnold   +5 more
wiley   +1 more source

Receptor-Selective Modulation of Cannabinoid Signaling by Cardamonin: Integrating Molecular Dynamics, Free Energy Calculations, and Behavioral Validation. [PDF]

ACS Omega
Khalid MH, Azmi L, Mubarak MQE, Iqma Marsujak NM, Syahir A, Perimal EK, Sulaiman MR, Mohamad Jamali MA.   +7 more
europepmc   +1 more source

The Role of Immunoresolvents in Atherosclerosis: A Mini‐Review on Their Biology and Therapeutic Opportunities

Health Science Reports, Volume 9, Issue 8, August 2026.
ABSTRACT Background and Aims Atherosclerosis is a lipid‐induced chronic inflammatory cardiovascular disorder denoted by the infiltration of immune cells and the agglomeration of lipids in the intima, the innermost layer, of the arteries of large and medium sizes.
Ramin Lotfi, Alireza Nasirifar, Hoda Rahmani, Sara Falahi, Meysam Kashiri   +4 more
wiley   +1 more source

Short Communication: The Peripheral Cannabinoid CB₁ Receptor Antagonist AM6545 Modifies Cardiovascular Effects of Endocannabinoids in DOCA-Salt Rats. [PDF]

Int J Mol Sci
Remiszewski P, Schlicker E, Grzęda E, Weresa J, Toczek M, Malinowska B.   +5 more
europepmc   +1 more source

Myocardial Lipid Metabolism Imbalance: The Pathological Core and Novel Diagnostic‐Therapeutic Directions of Cardiovascular Diseases

Journal of Biochemical and Molecular Toxicology, Volume 40, Issue 8, August 2026.
In cardiac cells, Plin5/AMPK regulate lipid homeostasis; excess CD36‐mediated uptake drives lipotoxicity, mitochondrial dysfunction, and CVDs (e.g., heart failure). Biomarkers (ApoB/ApoA‐1) and therapies (SGLT2 inhibitors) target this cascade. ABSTRACT Cardiac lipid metabolism is fundamental to myocardial energy homeostasis, with fatty acid oxidation ...
Peiyun Xie, Qun Zeng, Hongrui Wang, Meihua She   +3 more
wiley   +1 more source